论文部分内容阅读
基因工程益生菌治疗和预防霍乱澳大利亚研究人员合成了一种可以预防和治疗霍乱的细菌产物,该产物含一种可与霍乱毒素相结合并中和之的糖基化脂质。研究人员发现,在对霍乱毒素敏感的肾上腺细胞中进行的体外试验显示, 这种制剂能中和霍乱毒素99．95％的细胞毒活性。在体内,当2～3天的幼鼠接受中毒剂量的霍乱弧菌后,立即给小鼠足够益生菌,以后每1次／8h,共 48h。结果,对照组中11／12例小鼠死亡,1例濒于死亡。而治疗组8／11例仍存活。当给霍乱菌1h或 4h后,再喂益生菌,治疗组中的幼鼠生存时间和生存数明显多于对照组。总之,类似神经节苷脂GMI 的益生菌是治疗霍乱的有前途药物,它们能用基因工程低价大规模生产,不会产生抗生素的耐药问题 (Gastroenterology,2006,130:1688～1695)。
Genetically engineered probiotics for the treatment and prevention of cholera Australian researchers have synthesized a bacterial product that prevents and treats cholera, which contains a glycosylated lipid that binds to and neutralizes cholera toxin. The researchers found that in vitro tests in cholera toxin-sensitive adrenal cells showed that the formulation neutralized 99.95% of the cytotoxic activity of cholera toxin. In vivo, when 2 to 3 days old pups received toxic doses of Vibrio cholerae, immediately give enough probiotics in mice, every 1 / 8h, a total of 48h. As a result, 11/12 mice in the control group died and 1 died on the verge of death. The treatment group 8/11 cases still survived. When the cholera bacteria 1h or 4h, and then fed probiotics, the treatment group of young rats survival time and survival significantly more than the control group. In summary, probiotics that resemble ganglioside GMI are promising drugs for the treatment of cholera that can be genetically engineered to be produced on a large scale at low prices without antibiotic resistance (Gastroenterology, 2006, 130: 1688-1695).